IgG4-Related Diseases Market to Grow at a CAGR of 34.60% by 2034

Strategic Insights -

The IgG4-related disease market is projected to experience significant growth, driven by emerging therapies such as Obexelimab (XmAb5871) and others, as well as the approval of treatments like UPLIZNA. According to a report by DelveInsight, the market was valued at around USD 170 million in 2024 and is expected to grow at a notable CAGR during the 2020-2034 forecast period. The disease is characterized by elevated serum IgG4 levels and infiltration of IgG4-positive plasma cells in affected tissues, often affecting multiple organs.

Key Takeaways:

  • The IgG4-RD market is anticipated to grow at a CAGR of 34.60% by 2034 in leading countries like US, EU4, UK, and Japan.
  • Emerging therapies like Obexelimab (XmAb5871) and others are expected to enhance the IgG4-RD treatment landscape and drive market growth in the coming years.
  • Amgen received FDA approval for UPLIZNA, marking it as the first approved treatment for adults with IgG4-RD.
  • In 2024, there were approximately 148,970 diagnosed prevalent cases across the 7MM (U.S., EU4, UK, and Japan), with the United States accounting for the largest share.
  • Japan has been particularly active in case identification, recording roughly 38,690 diagnosed cases in 2024, a significant rise compared to 2015-2018.
  • Key pharmaceutical companies developing therapies for IgG4-RD include Amgen, Zenas BioPharma, Bristol Myers Squibb, Sanofi, Roche, AbbVie, Gilead Sciences, and Takeda Pharmaceutical Company.
  • In 2024, the United States held the largest share of the IgG4-RD market among the 7MM, generating approximately USD 90 million, while Japan's market was valued at nearly USD 6 million and is projected to grow at a significant CAGR from 2025 to 2034.

Statistics:

  • The IgG4-RD market was valued at around USD 170 million in 2024.
  • The market is expected to grow at a CAGR of 34.60% by 2034.
  • There were approximately 148,970 diagnosed prevalent cases across the 7MM in 2024.
  • Japan recorded roughly 38,690 diagnosed cases in 2024, a significant rise compared to 2015-2018.
  • In 2024, the United States generated approximately USD 90 million in the IgG4-RD market, while Japan's market was valued at nearly USD 6 million.

Sources:

  • DelveInsight report titled "IgG4-Related Diseases - Market Insights, Epidemiology, and Market Forecast 2034"
  • M2 PressWIRE article titled "IgG4 - Related diseases Market: Epidemiology, Therapies, Companies, DelveInsight | Roche, AbbVie, Gilead Sciences, Takeda Pharmaceutical Company"
  • Amgen press release announcing the approval of UPLIZNA for the treatment of adults with IgG4-RD.